spacer
home > epc
PUBLICATIONS

European Pharmaceutical Contractor

 

Published quarterly, European Pharmaceutical Contractor (EPC) covers the essential contract research issues between pharma companies and their CRO partners. The title, which is integrated within International Clinical Trials (ICT) magazine, offers a strategic view of the drug development industry – giving its pharma, biotech and CRO readership expert insight and analysis on the sponsor-service provider landscape.

EPC focuses on key trends, concerns and developments in contract research operations across the drug development spectrum, from preclinical to post-marketing. It explores the shifting collaborative needs and practical implications for sponsors and their contract partners, with the emphasis on building and managing effective collaborations.

Prompted by the synergies between outsourcing and trial operations, EPC joined forces with sister brand ICT in late-2015, in a move that brings added value to both brands. With EPC now an inserted edition within ICT, industry practitioners across these complementary subject areas now have unrivalled access to a wealth of shared views and analyses.

For further information please contact:

Advertising
Nicholas Matthews 

Editorial
Tom Allaway

We're also on Twitter! Follow us @EPCmagazine


 

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.


epc
 
 
Featured in this issue
Central Labs
Good Laboratory Practices

Ticking Boxes

Having a comprehensive checklist of Good Laboratory Practices within immuno-oncology trials can simplify study processes, as Elizabeth Koury and Jeff Mayhew at LabConnect suggest.
Outsourcing
Equipment Rental Considerations
Healthy Hiring

Robin Salter at KWIPPED and Valere Horath at Quipment explain what considerations need to be made when renting equipment for a clinical trial.

 
  Central Labs
Biomarkers and Assay Development

Marking Safety

New biomarkers are being evaluated as a promising solution to the threat of sepsis, as Professor Christene Leiper at Onorach explores.

spacer



Published quarterly in
February, May,
August and November


 

Industry Events

4th Annual Formulation & Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 4th Annual Formulation & Drug Delivery Congress, 8th – 9th May 2018, London, UK.Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 40 presentations and case studies focused on the key issues in large molecule and small molecule drug formulation and drug delivery.
More info >>

 
News and Press Releases

Dempsey Demystifies Regulatory Cycle at DIA Europe

March 22, 2018 (Hartford, Conn.) – RWS Life Sciences Managing Director, Sheena Dempsey, will present “Demystifying the Multilingual Complexities in the Regulatory Cycle” at DIA Europe 2018, on April 17, at 3:30PM (CET), in Basel, Switzerland.
More info >>

air transport logo

 

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement